Despite the effectiveness of multiple combinations of anti-HIV chemotherapy that was introduced for the management of HIV infection, there are still a number of critical unresolved issues in HIV chemotherapy. It is clear that existing drugs are not always effective primarily due to lack of potency, development of resistant virus, poor pharmacokinetics, lack of penetration into virus reservoirs, drug interactions affecting safety of the drug, oral bioavailability, and poor compliance by HIV infected patients. Based on our knowledge of the molecular biology of HIV, medicinal chemistry know-how, as well as pharmacological approach, our group is uniquely qualified to tackle these challenges. Some of the issues addressed in this proposal are the viral replication in lymphatic systems, targeted drug delivery, dementia and the brain as a viral reservoir, viral resistance and drug combination and interactions. Our proven track record in designing and synthesizing more selective and potent antiviral agents to achieve these goals is well established. During the previous funding period, we developed a promising prodrug, (-)- b-D-2,6-diaminopurine dioxolane (DAPD), which is currently undergoing Phase II clinical trials by Triangle Pharmaceuticals. DAPD is not only a potent anti-HIV agent, but also it has demonstrated a favorable viral resistant profile in vitro as well as in vivo, which is necessary for salvage therapy for AIDS patients. Therefore, DAPD has been designated as a """"""""fast-track"""""""" compound by the FDA. In order to further improve the potency, bioavailability, and selective targeted delivery to the lymphatic system and brain, we propose several prodrugs of DAPD. Recently, we also discovered a new class of D-enantiomers of 2'-fluoro-unsaturated nucleosides, including 2'-F-D4A, 2'-F-D4l and 2'F-D4G with potent antiviral activity against mutant viruses. However, these purine nucleosides may be limited as useful agents due to their poor cellular transport. In this application, we proposed to synthesize various prodrugs to improve the potency as well as pharmacokinetic/pharmacodynamic profiles. Very recentiy, we also discovereda potent anti-HIV activity of D4G prodrug (6-cyclopropylamino-D4G), while D4G itself is practically inactive against HIV-1. We plan to conduct various biological evaluation to determine the full potential of this prodrug as a clinical candidate. This approach may be extended to other classes of antiviral agents. In summary, we will continue to study three classes of proposed prodrugs to improve their pharmacokinetics profiles in mice, rats and rhesus monkeys to enhance the efficacy of parent anti-HIV agents. If any prodrugs are found to be promising during these studies, we plan to advance them as clinical candidates.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Method to Extend Research in Time (MERIT) Award (R37)
Project #
5R37AI025899-21
Application #
7189936
Study Section
Special Emphasis Panel (NSS)
Program Officer
Nasr, Mohamed E
Project Start
1987-09-30
Project End
2011-05-31
Budget Start
2007-06-01
Budget End
2008-05-31
Support Year
21
Fiscal Year
2007
Total Cost
$491,584
Indirect Cost
Name
University of Georgia
Department
Pharmacology
Type
Schools of Pharmacy
DUNS #
004315578
City
Athens
State
GA
Country
United States
Zip Code
30602
Rawal, Ravindra K; Singh, Uma S; Chavre, Satish N et al. (2013) 2'-Fluoro-6'-methylene-carbocyclic adenosine phosphoramidate (FMCAP) prodrug: in vitro anti-HBV activity against the lamivudine-entecavir resistant triple mutant and its mechanism of action. Bioorg Med Chem Lett 23:503-6
Bondada, Lavanya; Detorio, Mervi; Bassit, Leda et al. (2013) Adenosine Dioxolane Nucleoside Phosphoramidates as Antiviral Agents for Human Immunodeficiency and Hepatitis B Viruses. ACS Med Chem Lett 4:747-751
Herman, Brian D; Schinazi, Raymond F; Zhang, Hong-wang et al. (2012) Substrate mimicry: HIV-1 reverse transcriptase recognizes 6-modified-3'-azido-2',3'-dideoxyguanosine-5'-triphosphates as adenosine analogs. Nucleic Acids Res 40:381-90
Schinazi, Raymond F; Bassit, Leda; Clayton, Marcia M et al. (2012) Evaluation of single and combination therapies with tenofovir disoproxil fumarate and emtricitabine in vitro and in a robust mouse model supporting high levels of hepatitis B virus replication. Antimicrob Agents Chemother 56:6186-91
Nie, Ting; Detorio, Mervi; Schinazi, Raymond F (2011) Universal profiling of HIV-1 pol for genotypic study and resistance analysis across subtypes. Antivir Ther 16:1267-75
Wang, Jianing; Singh, Uma S; Rawal, Ravindra K et al. (2011) Antiviral activity of novel 2'-fluoro-6'-methylene-carbocyclic adenosine against wild-type and drug-resistant hepatitis B virus mutants. Bioorg Med Chem Lett 21:6328-31
Zhang, Hong-Wang; Detorio, Mervi; Herman, Brian D et al. (2011) Synthesis, antiviral activity, cytotoxicity and cellular pharmacology of l-3'-azido-2',3'-dideoxypurine nucleosides. Eur J Med Chem 46:3832-44
Cho, Jong Hyun; Amblard, Franck; Coats, Steven J et al. (2011) Efficient synthesis of nucleoside aryloxy phosphoramidate prodrugs utilizing benzyloxycarbonyl protection. Tetrahedron 67:5487-5493
Gadthula, Srinivas; Rawal, Ravindra K; Sharon, Ashoke et al. (2011) Synthesis and antiviral activity of cyclopropyl-spirocarbocyclic adenosine, (4R,5S,6R,7R)-4-(6-amino-9H-purin-9-yl)-7-(hydroxymethyl)spiro[2.4]heptane-5,6-diol against hepatitis C virus. Bioorg Med Chem Lett 21:3982-5
Roy, Vincent; Obikhod, Aleksandr; Zhang, Hong-Wang et al. (2011) Synthesis and anti-HIV evaluation of 3'-triazolo nucleosides. Nucleosides Nucleotides Nucleic Acids 30:264-70

Showing the most recent 10 out of 113 publications